# US 2016/0235769 A1 · Compositions for the treatment of inflammation of the gastrointestinal tract

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0235769 A1
- Document ID: US20160235769A1
- Status: Published application
- Kind: A1
- Application number: 15/136,372
- Filed: 2016-04-22
- Published: 2016-08-18
- Earliest claimed: 2007-11-13
- Assignees: Meritage Pharma, Inc.
- Applicants: Meritage Pharma, Inc.
- Inventors: Malcolm Hill
- Web page: https://patentgrep.com/patent/US20160235769A1

## CPC

- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 9/0065: {Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus}
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods for treating the symptoms of and inflammation associated with gastroesophageal reflux disease (GERD) and other conditions. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

## Claims

### Claim at position 1

1-42. (canceled)

### Claim 43

A method of treating or alleviating the symptoms of, or inflammation due to, gastroesophageal reflux disease (GERD) in an individual comprising orally administering for topical delivery to the gastrointestinal tract a therapeutically effective amount of a corticosteroid to the individual, the corticosteroid orally administered to the esophagus of the individual in the form of a pharmaceutical composition having a viscosity of at least 2 cP.

### Claim 44 (depends on 43)

The method of claim 43, wherein the gastroesophageal reflux disease is nonerosive reflux disease (NERD).

### Claim 45 (depends on 44)

The method of claim 44, wherein the nonerosive reflux disease is diagnosed using a symptom score analysis and, optionally, an endoscopic evaluation.

### Claim 46 (depends on 43)

The method of claim 43, wherein the gastroesophageal reflux disease is erosive esophagitis (EE).

### Claim 47 (depends on 46)

The method of claim 46, wherein the gastroesophageal reflux disease is LA grade C or D erosive esophagitis.

### Claim 48 (depends on 43)

The method of claim 43, wherein the method further comprises administering to the individual a second therapeutic agent, which is not an anti-inflammatory agent.

### Claim 49 (depends on 48)

The method of claim 48, wherein the second therapeutic agent is selected from a proton pump inhibitor (PPI), a histamine receptor antagonist (H2RA), a GABAB receptor agonist, TLESR-reducing agent (such as a GABAB agonist or an mGluR5 antagonist), a potassium-competitive acid blocker (P-CAB), a mucosal protectant, a histamine H3 agonist, an acetylcholine modulator, 5HT4 receptor agonist, 5HT3 receptor antagonist, 5HT1 receptor antagonist, or a combination of two or more thereof.

### Claim 50 (depends on 43)

The method of claim 43, wherein the therapeutically effective amount of the corticosteroid is an amount sufficient to reduce expression or activity of one or more infiltrates.

### Claim 51 (depends on 50)

The method of claim 50, wherein the one or more infiltrates, the expression or activity of which are reduced, comprise eosinophils, neutrophils or T-cells.

### Claim 52 (depends on 43)

The method of claim 43, wherein the therapeutically effective amount of the corticosteroid is an amount sufficient to reduce expression or activity of one or more inflammatory cytokines.

### Claim 53 (depends on 52)

The method of claim 52, wherein the one or more cytokines, the expression or activity of which are reduced, comprise one or more of IL-1, IL-4, IL-6, IL-8, IL-13, INF-α, INF-γ, TNF, eotaxin, RANTES, and/or RNANTES.

### Claim 54 (depends on 43)

The method of claim 43, wherein the therapeutically effective amount of the corticosteroid is an amount sufficient to enhance function of the lower esophageal sphincter.

### Claim 55 (depends on 43)

The method of claim 43, wherein the therapeutically effective amount of the corticosteroid is an amount sufficient to enhance esophageal smooth muscle contraction.

### Claim 56 (depends on 43)

The method of claim 43, wherein the corticosteroid is a topical corticosteroid.

### Claim 57 (depends on 56)

The method of claim 56, wherein the topical corticosteroid is budesonide.

### Claim 58 (depends on 56)

The method of claim 56, wherein the topical corticosteroid is fluticasone propionate.

### Claim 59 (depends on 43)

The method of claim 43, wherein about 100 μg/day to about 20 mg/day of the corticosteroid is administered to the individual.

### Claim 60 (depends on 59)

The method of claim 59, wherein between 300 μg/day and 4 mg/day of the corticosteroid is administered to the individual.

### Claim 61 (depends on 43)

The method of claim 43, wherein the gastroesophageal reflux disease (GERD) is refractory to an acid inhibitor.

### Claim 62 (depends on 43)

The method of claim 43, further comprising administering a therapeutically effective amount of an H2RA to said individual.

### Claim 63 (depends on 62)

The method of claim 62, wherein the corticosteroid and H2RA are administered concurrently.

### Claim 64 (depends on 62)

The method of claim 62, wherein the H2RA is selected from cimetidine, famotidine, nizatidine, and ranitidine.

### Claim 65 (depends on 64)

The method of claim 64, wherein the H2RA is ranitidine.

### Claim 66 (depends on 62)

The method of claim 62, wherein the H2RA is administered in an amount of between 1 mg and 500 mg.

### Claim 67 (depends on 43)

The method of claim 43, further comprising administering a therapeutically effective amount of a proton pump inhibitor to said individual.

### Claim 68 (depends on 67)

The method of claim 67, wherein the corticosteroid and the proton pump inhibitor are administered concurrently.

### Claim 69 (depends on 68)

The method of claim 68, wherein the proton pump inhibitor is selected from omeprazole, hydroxyomeprazole, esomeprazole, tenatoprazole, lansoprazole, pantoprazole, rabeprazole, dontoprazole, habeprazole, perprazole, ransoprazole, pariprazole, leminoprazole, S-tenatoprazole-Na, and dexlansoprazole.

### Claim 70 (depends on 69)

The method of claim 69, wherein the proton pump inhibitor is omeprazole.

### Claim 71 (depends on 67)

The method of claim 67, wherein the proton pump inhibitor is administered in an amount of between 1 mg and 600 mg.

### Claim 72 (depends on 67)

The method of claim 67, further comprising administering a therapeutically effective amount of an H2RA to said individual.

### Claim 73 (depends on 43)

The method of claim 43, wherein the corticosteroid is administered in the form of a pharmaceutical composition comprising the corticosteroid and at least one excipient.

### Claim 74 (depends on 73)

The method of claim 73, wherein the excipient increases the interaction of the composition with the individual's esophagus.

### Claim 75 (depends on 43)

The method of claim 43, wherein the viscosity of the composition is about 200 cP to about 600 cP, and wherein the viscosity is measured at 25 degrees Celsius and a shear rate of about 13.2 sec−1.

### Claim 76 (depends on 74)

The method of claim 74, wherein the excipient comprises a viscosity enhancer, a mucoadhesive agent, an absorption enhancing agent, or a combination thereof.

### Claim 77 (depends on 76)

The method of claim 76, wherein the excipient comprises a viscosity-enhancing excipient, which is selected from acacia (gum arabic), agar, aluminum magnesium silicate, sodium alginate, sodium stearate, bladderwrack, bentonite, carbomer, carrageenan, Carbopol, cellulose, microcrystalline cellulose (MCC), ceratonia, chondrus, dextrose, furcellaran, gelatin, Ghatti gum, guar gum, hectorite, lactose, sucrose, maltodextrin, mannitol, sorbitol, honey, maize starch, wheat starch, rice starch, potato starch, gelatin, sterculia gum, xanthum gum, polyethylene glycol (e.g. PEG 200-4500), gum tragacanth, ethyl cellulose, ethylhydroxyethyl cellulose, ethylmethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, poly(hydroxyethyl methacrylate), oxypolygelatin, pectin, polygeline, povidone, propylene carbonate, methyl vinyl ether/maleic anhydride copolymer (PVM/MA), poly(methoxyethyl methacrylate), poly(methoxyethoxyethyl methacrylate), hydroxypropyl cellulose, hydroxypropylmethyl-cellulose (HPMC), sodium carboxymethyl-cellulose (CMC), silicon dioxide, polyvinylpyrrolidone (PVP: povidone), Splenda® (dextrose, maltodextrin and sucralose) and combinations thereof.

### Claim 78 (depends on 77)

The method of claim 77, wherein the viscosity-enhancing excipient is a combination of MCC and CMC.

### Claim 79 (depends on 78)

The method of claim 78, wherein the CMC/MCC combination has a mixed weight ratio of about 11/89.

### Claim 80 (depends on 76)

The method of claim 76, wherein the excipient comprises a mucoadhesive agent, which is selected from a soluble polyvinylpyrrolidone polymer (PVP); a water-swellable, but water-insoluble, fibrous, cross-linked carboxy-functional polymer, a cross-linked poly(acrylic acid), a carbomer homopolymer, a carbomer copolymer, a hydrophilic polysaccharide gum, maltodextrin, a cross-linked alignate gum gel, a water-dispersible polycarboxylated vinyl polymer, and combinations thereof.

### Claim 81 (depends on 80)

The method of claim 80, wherein the mucoadhesive agent is selected from at least of titanium dioxide, silicon dioxide, and clay, and mixtures thereof.

### Claim 82 (depends on 76)

The method of claim 76, wherein the excipient comprises an absorption enhancing agent, which is selected from acylcarnitines, surfactants, sodium lauryl sulfate, saponins, bile salts or bile acids including but not limited to cholanic acid, chilic acid, deoxycholic acid, glycocholic acid, tautocholic acid, chenodeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, isourosde oxycholic acid, lagodeoxycholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid, hyodeoxycholic acid, or combinations thereof, dihydrofusidates, fatty acid derivatives, chitosan, carbopol, cellulosic agents, sterols, including but not limited to alcohols structurally related to steroids, including but not limited to cholestanol, coprostanol, cholesterol, epicholesterol, ergosterol, ergocalciferol, or combinations thereof, starch, dextran, cyclodextrin, and combinations thereof.

### Claim 83 (depends on 43)

The method of claim 43, wherein the corticosteroid is administered in a unit dose formulation for oral administration.

### Claim 84 (depends on 43)

The method of claim 43, wherein the viscosity of the composition is about 2 cP to about 200 cP, and wherein the viscosity is measured at 25 degrees Celsius and a shear rate of about 13.2 sec−1.

### Claim 85

A method of treating or alleviating the symptoms of, or inflammation due to, gastroesophageal reflux disease (GERD) in an individual comprising orally administering for topical delivery to the esophagus of the individual a therapeutically effective amount of a corticosteroid to the individual, the corticosteroid orally administered in the form of a pharmaceutical composition, wherein the corticosteroid is the sole pharmaceutically active ingredient of the composition.

### Claim 86 (depends on 85)

The method of claim 85, wherein the viscosity of the composition is about 2 cP to about 200 cP, and wherein the viscosity is measured at 25 degrees Celsius and a shear rate of about 13.2 sec−1.
